Obesity Treatment

Business

Regeneron Aims to Redefine Obesity Treatment with Dual-Action Drug Targeting Weight and Cholesterol

Regeneron Pharmaceuticals is positioning its experimental obesity drug, olatorepatide, as a potential game-changer by combining significant weight loss with a dramatic reduction in 'bad' cholesterol. The company believes this dual benefit could carve out a unique niche in the competitive $150 billion market, currently led by Novo Nordisk and Eli Lilly.

Jan 30, 2026

Business

Medicare's Obesity Drug Coverage Set to Fuel Lilly's Weight-Loss Pill Launch, CEO Says

Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.

Feb 2, 2026

Business

Eli Lilly Bets $3.5 Billion on Pennsylvania Plant, Doubling Down on Obesity Drug Future

Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.

Feb 2, 2026

Business

Veralto Q4 Earnings Preview: Water Treatment Giant Faces Growth Test Amid Sector Momentum

Veralto Corp. is set to report fourth-quarter earnings after Tuesday's market close, with investors watching for signs of sustained growth in water analytics and treatment demand. The report comes amid mixed signals from the broader environmental services sector.

Feb 2, 2026

Business

Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data

Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.

Jan 30, 2026

Business

Eli Lilly Bets Big on Pennsylvania with $3.5 Billion Plant for Next-Gen Weight Loss Drugs

The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.

Feb 2, 2026

Business

Eli Lilly Doubles Down: $3.5 Billion Bet on Next-Gen Obesity Drugs and Gene Therapy Partnerships

Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.

Feb 2, 2026

Business

AstraZeneca Bets $18.5 Billion on CSPC's Monthly Obesity Shot in Major Pipeline Push

In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.

Jan 30, 2026

FDA Rejects Aquestive's Oral Anaphylaxis Treatment, Leaving Patients Awaiting Epinephrine Alternative

The U.S. Food and Drug Administration has issued a complete response letter for Aquestive Therapeutics' oral film drug designed to treat severe allergic reactions, the company announced Monday, delaying a potential new option for millions at risk.

Feb 2, 2026

Business

Cogent Biosciences Gains Key FDA Designations for Bezuclastinib, Spotlighting GIST Treatment Potential

Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.

Feb 2, 2026

Business

Beyond GLP-1: Eli Lilly Diversifies Pipeline with Autoimmune, Gene Editing Deals and Cancer Therapy Win

Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.

Jan 30, 2026

Business

Pfizer's $23 Billion Oncology Bet: CEO Albert Bourla's Post-Pandemic Quest to 'Save the World from Cancer'

After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.

Jan 30, 2026

Business

Citi Boosts Lexicon Pharmaceuticals Outlook on Novo Nordisk Partnership Progress

Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.

Jan 30, 2026

Business

Novo Nordisk Pivots: Oral Wegovy Launch, Job Cuts, and a Cell Therapy Bet Reshape Its Future

Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.

Jan 30, 2026

Business

AstraZeneca Bets $1.2 Billion on CSPC's Weight-Loss Drug Pipeline in Major China Deal

British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.

Jan 30, 2026

Business

Eli Lilly Bets Nearly $2 Billion on Repertoire Immune Medicines to Pioneer Next-Generation Autoimmune Therapies

Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.

Feb 2, 2026

Business

Rhythm Pharmaceuticals: The Under-the-Radar Biotech Outpacing Tech Giants

While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.

Feb 2, 2026

Business

FDA Expands Glaukos' iDose TR Implant Approval, Paving Way for Repeat Use in Glaucoma Management

Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.

Feb 2, 2026

Business

Glaukos Gains FDA Nod for Repeat iDose TR Implant, Bolstering Its Long-Term Glaucoma Platform Strategy

The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.

Feb 2, 2026

Business

Arbor Realty Trust's Tax Break for 2025 Dividends Fails to Ease Deepening Analyst Pessimism

While Arbor Realty Trust offers shareholders clarity on favorable tax treatment for 2025 dividends, analysts remain focused on a deteriorating earnings outlook and a 'Strong Sell' rating, casting doubt on the stock's near-term prospects.

Feb 2, 2026